Annie Ellis

Join us this month in recognizing the more than 18 million cancer survivors in the United States and the work being done to improve the lives of all survivors and their caregivers. spr.ly/6016exfCu #NationalCancerSurvivorsMonth

🗣️Excited to share our research on patient-provider communication at #ASCO24. Our research finds that although most with #breastcancer say communication was good overall, less than 1/3 felt that long term #bcsm side effects were explained. Let's talk about why this MATTERS. 🧵1/

#gyncsm Exercise is beneficial! Thanks @LarissaAMeyerMD for this study .

Now at @ASCO: Gastrointestinal oncologist Dr. @AndreaCercek shares updated results on a small but heralded clinical trial which showed 100% of patients with locally advanced #rectalcancer had a complete response to #immunotherapy alone. Learn more: bit.ly/3V6r7Lh #ASCO24

Congrats @LarissaAMeyerMD! So Important! #Move4Her Everyone can join the movement to increase QOL among patients, while increasing awareness & research funding for GYN Cancers!! Share with all patients and providers to register at: 2024-move4her.raiselysite.com @RiosDoriaMD @GYNCancer

#ASCO24 session, “State of the Art in Gynecologic Cancer: New Drugs and Companion Diagnostics” will focus on companion diagnostics and differences between germline and genomic testing for patients with gynecologic cancers. bit.ly/3R1wrOV (1/3)

Extremely important discussion on Oncology Drug Shortages at #ASCO24

#gyncsm #ASCO24 Au-Yeung : Melanomas in the gyn tract -rare disease No consensus on staging Novel therapies being tested.

Good morning #ASCO24! Don’t forget to stop by the @theNCI exhibit booth (#12023). Our terrific staff are ready to answer your questions, and you can add to our inspiration board about #CancerResearch training and mentorship topics.

Treatment has to be TOLERABLE before it can be EFFECTIVE (even allowing for the understandable difficulty healing in time for adjuvant FLOT, I don't understand the ~1/3rd of patients who couldn't complete pre-op in CROSS, especially when it was <10% over a decade ago!) #ASCO24

#ASCO24 @ramsedhom’s beautiful humane talk “Good News, Bad News: The Paradox of Cancers w/ Targeted Therapies”: We need to relinquish need to fix things, realize tumor isn’t the only target, & meet patients’ bids for support (& unlearn habits of responding to such bids w/ data).

"We can't always fix but we can always comfort" -- @ramsedhom #hpm #ASCO24

#ASCO24 AGO 2.29 chemo+bev +/- atezo: once again CPI fail to meaningfully impact survival. Front line: ATHENA COMBO reported negative in press release this week, Plat sensitive: ATALANTE and ANITA both negative and now second plat resistant study neg. Time to move on....

#ASCO24 #Plenary: RCT of early #PalliativeCare in person or via #telehealth (N=1250) in recently diag metastatic #lungcancer demonstrates equiv in primary endpoint of self-reported quality of life at wk 24. We need widespread access to high quality telehealth long-term. #lcsm

#ASCO24 strong biomarker work presented by Dr. Katherine Fuh for GOG 3059. Overall neg phase 3 but high AXL probably matters. What’s next

And Helen who gave me hope 18 years ago.

Today at #ASCO24 it was a day of gyn cancer presentations and making connections with clinicians and advocates #gyncsm

Gourley discussing low grade serous OC treatments: MAPK assoc tumors better outcomes. Endocrine treatment studies being done.MEk inhibitors more work needs to be done. CDK 4/6 inhibitors possible #ASCO24 #gyncsm

#ASCO24 #gyncsm @amandanfader on neuroendocrine carcinoma of the cervix Rare tumor cancers need collaboration between cancer centers Most NECC are HPV related @SGO_org has guidelines for NECC . Swog S2012 study of plat/ etoposide/ atezolizumab enrolling

.@Neil_Iyengar chats about phase 2 results of the effects of plant-based diet & exercise therapy on weight & body composition in patients with primary hormone receptor positive #breastcancer during poster sessions at @ASCO. bit.ly/3V9DE0y #ASCO24